- Solid Biosciences has entered a non-exclusive worldwide licence and collaboration agreement with Andelyn Biosciences for the use of its AAV-SLB101 capsid.
- The agreement will allow Andelyn to offer AAV-SLB101 to its gene therapy clients as part of its AAV Curator® manufacturing platform.
Solid Biosciences Inc. has announced a non-exclusive worldwide licence and collaboration agreement with Andelyn Biosciences for the use of its proprietary AAV-SLB101 capsid. Andelyn, a cell and gene therapy CDMO, will integrate the capsid into its modular AAV Curator® Platform to support gene therapy manufacturing programmes.
Under the agreement, Solid will allow Andelyn to offer AAV-SLB101 to its gene therapy clients in combination with both suspension and adherent processes within the AAV Curator® Platform. Specific financial terms were not disclosed. Solid noted that the platform is designed to optimise contract manufacturing processes through a configurable materials approach.
AAV-SLB101 was developed to enhance skeletal muscle and cardiac tropism with reduced liver biodistribution. As of the safety cut-off date of 31 October 2025, it has been generally well tolerated in 23 paediatric participants in Solid’s Phase 1/2 INSPIRE DUCHENNE clinical trial evaluating investigational gene therapy SGT-003. Preclinical work and early clinical data have shown robust cardiac and skeletal muscle transduction.
“We are excited to announce a new non-exclusive license for AAV-SLB101 with Andelyn Biosciences. This collaboration reflects our shared mission to accelerate the next generation of gene therapies built upon cutting-edge technologies designed to enhance safety and efficacy.”
Bo Cumbo, President and CEO of Solid Biosciences
Matt Niloff, Chief Commercial Officer at Andelyn, said the agreement will provide clients with access to “an advanced gene therapy vector that has been clinically validated”, and noted that integration with the AAV Curator® Platform could support faster and more cost-effective development.
